| 查看: 343 | 回复: 2 | |||
也到木虫 (小有名气)
无欲无求
|
[求助]
求linifanib最新临床情况 已有1人参与
|
|
求linifanib最新临床情况，最好包括临床类型及几期 还有这种药物的发展前景 |
回复此楼» 猜你喜欢
医药口服制剂辅料应用
已经有0人回复
-
全新推出Tguide®靶向递送方案，突破99% T细胞转染效率
已经有1人回复
-
药理学论文润色/翻译怎么收费?
已经有141人回复
-
Mal-LN29-LNP-mRNA 试剂盒：自带Mal基团，一盒实现抗体筛选与体内靶向验证
已经有0人回复
-
自由偶联 | 脾脏靶向：抗体偶联空载LNP试剂盒
已经有0人回复
-
SM-102 试剂盒，告别纳米制备仪！
已经有0人回复
-
2026年辅料登记预告
已经有1人回复
-
SPguide®：小鼠体内脾脏转染的一键解决方案
已经有0人回复
-
高效肺靶向RNA转染，加速肺部RNA药物开发
已经有2人回复
-
二糖的糖脂，合成后sephadex LH-20分离不出来，求助
已经有1人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 求华西药学院临床药学考研资料
已经有7人回复
- 求中南大学口腔临床医学的真题及资料
已经有5人回复
- 求指导，临床药学就业前景
已经有5人回复
- 求一名临床药学专业的博士生导师
已经有6人回复
- 【求助】药物临床Ia期是什么意思?求详解
已经有8人回复
2楼2014-08-20 10:46:28
【答案】应助回帖
感谢参与，应助指数 +1
| AbbVie is developing linifanib, an orally active multi-targeted receptor tyrosine kinase inhibitor, for the treatment of cancer, including non-small cell lung cancer, breast cancer, colorectal cancer, renal cancer and hepatocellular carcinoma. Linifanib was being developed in collaboration with Genentech; however, development later reverted to Abbott. Linifanib acts as both a vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitor. It has been shown to stop disease progression by limiting tumour blood-flow. Linifanib is hydrophobic, but is oxidised in the body to A 849529, a hydrophilic metabolite that includes both carboxyl and amino groups. Linifanib is in phase II development for breast, renal, colorectal and non-small cell lung cancer. The compound was being investigated in a phase III trial for hepatocellular carcinoma, but the trial has been terminated. |
» 本帖附件资源列表
-
欢迎监督和反馈：小木虫仅提供交流平台，不对该内容负责。
本内容由用户自主发布，如果其内容涉及到知识产权问题，其责任在于用户本人，如对版权有异议，请联系邮箱：xiaomuchong@tal.com - 附件 1 : Linifanib-临床开发情况.docx
2014-08-20 14:47:24, 87.78 K
3楼2014-08-20 14:46:14